Similar articles

• Troxacitabine in leukemia.

  Swords R, Apostolidou E, Giles F. Swords R, et al. Hematology. 2006 Oct;11(5):321-9. doi: 10.1080/10245330601027316. Hematology. 2006. PMID: 17607581 Review.
• [Troxacitabine].

  Gourdeau H, Jolivet J. Gourdeau H, et al. Bull Cancer. 2004 Mar;91(3):213-8. Bull Cancer. 2004. PMID: 15171046 Review. French.
• Troxacitabine-based therapy of refractory leukemia.

  Giles FJ. Giles FJ. Expert Rev Anticancer Ther. 2002 Jun;2(3):261-6. doi: 10.1586/14737140.2.3.261. Expert Rev Anticancer Ther. 2002. PMID: 12113049 Review.
• Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.

  Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, Kantarjian HM. Giles FJ, et al. J Clin Oncol. 2001 Feb 1;19(3):762-71. doi: 10.1200/JCO.2001.19.3.762. J Clin Oncol. 2001. PMID: 11157029 Clinical Trial.
• Troxacitabine: BCH 4556, SPD 758, Troxatyl.

  Adis International Ltd. Adis International Ltd. Drugs R D. 2003;4(4):264-8. doi: 10.2165/00126839-200304040-00010. Drugs R D. 2003. PMID: 12848594